Elicio Therapeutics (ELTX) Research & Development (2020 - 2026)
Elicio Therapeutics posted quarterly Research & Development of $6.8 million for Q1 2026, down 13.13% year-on-year from $7.8 million in Q1 2025, and up 33.01% on a QoQ basis from $5.1 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Research & Development data on file, last reported at $6.8 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 13.13% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (down 29.5% YoY), and the FY2025 full-year result was $24.9 million, down 26.01% from the prior year.
- Research & Development for Q1 2026 stood at $6.8 million, up from $5.1 million in the prior quarter.
- Across five years, Research & Development topped out at $11.7 million in Q1 2022 and bottomed at $4.3 million in Q4 2022.
- The 5-year median for Research & Development is $6.8 million (2026), against an average of $6.8 million.
- The widest annual swing landed in 2022, when Research & Development sank 65.43%; it then soared 73.93% in 2024.
- A 5-year view of Research & Development shows it stood at $4.3 million in 2022, then jumped by 43.52% to $6.2 million in 2023, then jumped by 73.93% to $10.7 million in 2024, then slumped by 52.56% to $5.1 million in 2025, then soared by 33.01% to $6.8 million in 2026.
- The last three Research & Development figures came in at $6.8 million (Q1 2026), $5.1 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | 6.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | 5.08 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.78 Mn |
| Dec 31, 2024 | 10.71 Mn |
| Sep 30, 2024 | 7.21 Mn |
| Jun 30, 2024 | 8.18 Mn |
| Mar 31, 2024 | 7.56 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Sep 30, 2023 | 7.26 Mn |
| Jun 30, 2023 | 4.94 Mn |
| Mar 31, 2023 | 5.48 Mn |
| Dec 31, 2022 | 4.29 Mn |
| Sep 30, 2022 | 4.59 Mn |
| Jun 30, 2022 | 5.04 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 6.67 Mn |
| Sep 30, 2021 | 13.29 Mn |
| Jun 30, 2021 | 14.44 Mn |
| Mar 31, 2021 | 14.30 Mn |
| Dec 31, 2020 | 11.07 Mn |
| Sep 30, 2020 | 6.09 Mn |
| Jun 30, 2020 | 12.23 Mn |
| Mar 31, 2020 | 9.60 Mn |